Key Points
- Adaptive Biotechnologies insider Francis Lo sold 44,838 shares on July 2 at an average price of $22.59, for about $1.01 million. The sale was part of a pre-arranged Rule 10b5-1 trading plan, and it reduced his stake by 16.27%.
- Lo also made several earlier sales in recent months, including 51,004 shares on July 1, 39,741 shares on June 4, and 22,564 shares on April 8. Those transactions add to a pattern of ongoing insider selling.
- The stock has climbed near its 52-week high, opening at $21.50 versus a range of $9.96 to $22.80, while analysts remain broadly positive with an average “Moderate Buy” rating and a $20.50 target price. The company also recently beat quarterly EPS and revenue estimates on 35.1% year-over-year revenue growth.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) insider Susan Bobulsky sold 487 shares of the stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $22.00, for a total value of $10,714.00. Following the transaction, the insider directly owned 406,288 shares of the company's stock, valued at approximately $8,938,336. The trade was a 0.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Susan Bobulsky also recently made the following trade(s):
- On Thursday, June 11th, Susan Bobulsky sold 5,000 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $19.00, for a total value of $95,000.00.
- On Thursday, June 4th, Susan Bobulsky sold 11,000 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $18.00, for a total value of $198,000.00.
Adaptive Biotechnologies Price Performance
Shares of NASDAQ ADPT traded down $0.42 during midday trading on Tuesday, reaching $21.08. 42,487 shares of the stock traded hands, compared to its average volume of 2,258,578. The stock has a market capitalization of $3.37 billion, a PE ratio of -63.62 and a beta of 2.07. Adaptive Biotechnologies Corporation has a one year low of $9.96 and a one year high of $22.80. The company's 50 day moving average is $16.24 and its 200 day moving average is $15.90.
Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.03. The company had revenue of $70.87 million for the quarter, compared to analysts' expectations of $61.03 million. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. Adaptive Biotechnologies's quarterly revenue was up 35.1% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.20) earnings per share. As a group, equities analysts forecast that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current year.
Institutional Trading of Adaptive Biotechnologies
Institutional investors and hedge funds have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd purchased a new position in Adaptive Biotechnologies during the 4th quarter worth $28,000. EverSource Wealth Advisors LLC increased its stake in shares of Adaptive Biotechnologies by 197.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company's stock valued at $38,000 after buying an additional 1,565 shares during the period. KBC Group NV bought a new stake in shares of Adaptive Biotechnologies in the first quarter valued at about $45,000. Assetmark Inc. raised its holdings in shares of Adaptive Biotechnologies by 867.9% in the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company's stock valued at $49,000 after acquiring an additional 2,708 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. purchased a new stake in Adaptive Biotechnologies in the fourth quarter worth about $51,000. Institutional investors own 99.17% of the company's stock.
Analyst Upgrades and Downgrades
A number of analysts recently issued reports on ADPT shares. TD Cowen raised their price target on Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a "buy" rating in a research report on Wednesday, May 6th. Morgan Stanley cut their price target on shares of Adaptive Biotechnologies from $21.00 to $18.00 and set an "equal weight" rating on the stock in a report on Tuesday, May 12th. Guggenheim raised their price objective on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a "buy" rating in a research note on Monday, June 29th. BTIG Research restated a "buy" rating and set a $22.00 target price on shares of Adaptive Biotechnologies in a research report on Wednesday, June 17th. Finally, JPMorgan Chase & Co. cut their target price on Adaptive Biotechnologies from $21.00 to $19.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 6th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Adaptive Biotechnologies has an average rating of "Moderate Buy" and a consensus target price of $20.50.
Check Out Our Latest Stock Report on ADPT
About Adaptive Biotechnologies
(
Get Free Report)
Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.
The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
